Key terms
About VRTX
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest VRTX news
Yesterday
6:05am ET
Vertex Pharmaceuticals sees Q1 capex $20M-$205M
Yesterday
2:02am ET
Vertex’s High-Stakes Acquisition: Navigating the Uncertainties of the Alpine Deal
May 08
10:07pm ET
Stifel Nicolaus Reaffirms Their Hold Rating on Vertex Pharmaceuticals (VRTX)
May 08
11:11am ET
Biotech Alert: Searches spiking for these stocks today
May 07
8:56pm ET
Vertex Pharmaceuticals price target raised to $477 from $466 at UBS
May 07
8:17am ET
Oppenheimer Keeps Their Buy Rating on Vertex Pharmaceuticals (VRTX)
May 07
8:12am ET
Truist Financial Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX)
May 07
8:08am ET
Piper Sandler Releases a Buy Rating on Vertex Pharmaceuticals (VRTX)
May 07
8:07am ET
Vertex Pharmaceuticals (VRTX) Gets a Hold from RBC Capital
May 07
8:03am ET
Maintain Position on Vertex Pharmaceuticals: A Hold Rating Despite Strong Quarterly Performance
May 07
8:02am ET
Buy Rating on Vertex Pharmaceuticals: Promising Kidney Disease Treatments Poised for Market Growth
May 07
7:43am ET
Vertex Pharmaceuticals (VRTX) Receives a Buy from Barclays
May 07
4:25am ET
Buy Rating Affirmed for Vertex Pharmaceuticals on Strong Q1 Earnings and Expanding Market Presence
May 06
4:03pm ET
Vertex Pharmaceuticals affirms FY4 revenue view of $10.55B-$10.75B
May 06
4:03pm ET
Vertex Pharmaceuticals reports Q1 EPS $4.21, consensus $4.06
May 06
1:55pm ET
Notable companies reporting after market close
May 06
7:05am ET
Options Volatility and Implied Earnings Moves Today, May 06, 2024
May 06
7:01am ET
Options Volatility and Implied Earnings Moves This Week, May 06 – May 10, 2024
May 06
6:20am ET
Analysts Offer Insights on Healthcare Companies: Owens & Minor (OMI), Vertex Pharmaceuticals (VRTX) and Aldeyra Therapeutics (ALDX)
Apr 29
9:41pm ET
Analysts Offer Insights on Healthcare Companies: Accolade (ACCD), Vertex Pharmaceuticals (VRTX) and Zimmer Biomet Holdings (ZBH)
Apr 26
11:46am ET
Vertex announces European Commission approval for KALYDECO
Apr 26
11:02am ET
Cantor Fitzgerald healthcare analysts hold an analyst/industry conference call
Apr 24
7:30am ET
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), HealthStream (HSTM) and Vertex Pharmaceuticals (VRTX)
Apr 23
5:33am ET
Vertex Pharmaceuticals, TreeFrog Therapeutics announce licensing agreement
Apr 22
8:30am ET
Vertex Pharmaceuticals (VRTX) Gets a Buy from Piper Sandler
Apr 22
1:16am ET
Buy Rating on Vertex Pharmaceuticals: Risinger’s Confidence in VX-548’s Billion-Dollar Potential and FDA Progress
Apr 19
7:31pm ET
CRISPR Therapeutics Stock (NASDAQ:CRSP) Pushes Lower, But Fundamentals Are Intact
Apr 18
6:45pm ET
Buy Rating on Vertex Pharmaceuticals Fueled by Promising IgAN Therapy and Strategic Acquisition
Apr 18
12:15pm ET
Guggenheim Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX)
Apr 18
8:30am ET
Vertex Pharmaceuticals announces advancements in suzetrigine pain program
Apr 15
2:05pm ET
Novartis reports results from interim analysis of Phase 3 APPLAUSE-IgAN study
No recent press releases are available for VRTX
VRTX Financials
Key terms
Ad Feedback
VRTX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
VRTX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range